Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3217263 | 1.00 | CA2 (0.57) | CA2PTGS2CA1CA9CA12 | |
| SCHEMBL5206541 | 1.00 | CA2 (0.57) | CA2PTGS2CA1CA9CA12 | |
| SCHEMBL28589318 | 0.89 | ALDH1A1 (0.54) | CA2PTGS2CA1CA9SMN1; SMN2 | |
| SCHEMBL2454215 | 0.89 | ALDH1A1 (0.54) | CA2PTGS2CA1CA9SMN1; SMN2 | |
| SCHEMBL12416606 | 0.89 | PTGS2 (0.67) | CA2PTGS2CA1CA9CA12 | |
| SCHEMBL2454217 | 0.89 | ALDH1A1 (0.54) | CA2PTGS2CA1CA9SMN1; SMN2 | |
| SCHEMBL2455348 | 0.89 | PTGS2 (0.67) | CA2PTGS2CA1CA9CA12 | |
| SCHEMBL2455350 | 0.89 | PTGS2 (0.67) | CA2PTGS2CA1CA9CA12 | |
| SCHEMBL20186948 | 0.89 | PTGS2 (0.67) | CA2PTGS2CA1CA9CA12 | |
| SCHEMBL12416601 | 0.89 | PTGS2 (0.67) | CA2PTGS2CA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902157-B2 | Spirocyclic azetidin(one); e.g. 2,7-diazaspiro[3.5]nonan-1-one; T-type calcium channel blockers; Niemann-Pick C1-like (NPC1L1) antagonists | SCHERING CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902157-B2 | Spirocyclic azetidin(one); e.g. 2,7-diazaspiro[3.5]nonan-1-one; T-type calcium channel blockers; Niemann-Pick C1-like (NPC1L1) antagonists | SCHERING CORPORATION (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100160282-A1 | NOVEL DIPHENYLAZETIDINONES, PROCESS FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS AND THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-24 | — | — | US | disclosed |
| US-7674773-B2 | Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-03-09 | — | — | US | disclosed |
| US-7576200-B2 | Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-08-18 | — | — | US | disclosed |
| US-7488829-B2 | Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-02-10 | — | — | US | disclosed |
| US-20090005321-A1 | Phenylazetidinone Derivatives | MICROBIA, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005321-A1 | Phenylazetidinone Derivatives | MICROBIA, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-20080281092-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | AVENTIS PHARMA DEUTSCHLAND GMBH | 2008-11-13 | — | — | US | disclosed |
| US-20080070889-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-03-20 | — | — | US | disclosed |
| US-20080070889-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-03-20 | — | — | US | disclosed |
| US-20070208179-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | AVENTIS PHARMA DEUTSCHLAND GMBH | 2007-09-06 | — | — | US | disclosed |
| US-6992067-B2 | Diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2006-01-31 | — | — | US | disclosed |
| US-20050267038-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | AVENTIS PHARMA DEUTSCHLAND GMBH | 2005-12-01 | — | — | US | disclosed |
| EP-1345895-A1 | NOVEL 1,2-DIPHENZYLAZETIDINONES, METHOD FOR PRODUCING THE SAME, MEDICAMENTS CONTAINING SAID COMPOUNDS, AND THE USE THEREOF FOR TREATING DISORDERS OF THE LIPID METABOLISM | Aventis Pharma Deutschland GmbH (DE) | 2003-09-24 | — | — | EP | disclosed |
| US-20020137689-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-09-26 | — | — | US | disclosed |
| WO-2002050027-A1 | NOVEL 1,2-DIPHENZYLAZETIDINONES, METHOD FOR PRODUCING THE SAME, MEDICAMENTS CONTAINING SAID COMPOUNDS, AND THE USE THEREOF FOR TREATING DISORDERS OF THE LIPID METABOLISM | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-06-27 | — | — | WO | disclosed |
| US-5688785-A | ANTICHOLESTEROL AGENTS BY INHIBITION OF SYNTHESIS | SCHERING CORPORATION (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0766667-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORPORATION (US) | 1997-04-09 | — | — | EP | disclosed |
| WO-1995035277-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORPORATION (US) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080281092-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | QDPR, NDUFB6, NDUFB7 | CA2 4428/4885PTGS2 1626/4885CA1 4873/4885 |
| US-20020137689-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | QDPR, NDUFB7, NDUFB6 | CA2 4405/4885PTGS2 1532/4885CA1 4868/4885 |
| US-20050267038-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | QDPR, NDUFB6, NDUFB7 | CA2 4428/4885PTGS2 1626/4885CA1 4873/4885 |
| US-20080070889-A1 | AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM | CYP46A1, OPRD1, OPRK1 | CA2 3036/4885PTGS2 702/4885CA1 4521/4885 |
| US-20090005321-A1 | Phenylazetidinone Derivatives | TYR, AAAS, FANCD2 | CA2 4388/4885PTGS2 1231/4885CA1 4877/4885 |
| US-20100160282-A1 | NOVEL DIPHENYLAZETIDINONES, PROCESS FOR THEIR PREPARATION, MEDICAMENTS COMPRISING THESE COMPOUNDS AND THEIR USE | QDPR, NDUFB6, NDUFB7 | CA2 4428/4885PTGS2 1626/4885CA1 4873/4885 |
| US-20070208179-A1 | Novel diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | QDPR, NDUFB6, NDUFB7 | CA2 4428/4885PTGS2 1626/4885CA1 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.